Back to top
more

Mersana Therapeutics (MRSN)

(Real Time Quote from BATS)

$3.11 USD

3.11
203,949

-0.05 (-1.58%)

Updated Apr 30, 2024 11:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MRSN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Mersana Therapeutics, Inc. [MRSN]

Reports for Purchase

Showing records 161 - 180 ( 197 total )

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

11/14/2018

Company Report

Pages: 9

3Q18 Corporate Update; Work in Progress With Clinical Clarity During 1H19

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

11/14/2018

Company Report

Pages: 7

3Q18; Progress Toward Cohort Expansions for XMT-1536 and XMT-1522 in 2019

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

11/09/2018

Industry Report

Pages: 8

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

09/18/2018

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

09/18/2018

Company Report

Pages: 7

Partial Clinical Hold Lifted, but Changes in Dosing May Extend Development Time

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 166

09/17/2018

Company Report

Pages: 9

Partial Clinical Hold in the Rearview, But a Step Back in Development Speed Is Warranted; PT Increased to $23 From $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 167

09/10/2018

Daily Note

Pages: 15

Pre-ASH Catalyst Calendar For Stocks Under Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 168

08/16/2018

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 169

08/16/2018

Industry Report

Pages: 10

HEALTHCARE - 2018 Wedbush PacGrow Healthcare Conference: Day 2 Recap

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 170

08/16/2018

Company Report

Pages: 9

A Show Me Story With a Potential Near-Term Resolution of the Partial Clinical Hold

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 171

08/15/2018

Company Report

Pages: 6

Timelines for Lifting of XMT1522 Hold and XMT1536 Data become Clearer

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 172

07/20/2018

Company Report

Pages: 9

Fork in the Road Moment Early in Drug Development; Target Lowered to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 173

07/19/2018

Company Report

Pages: 7

Clinical Hold Should Be a Temporary and Manageable Setback

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 174

06/06/2018

Company Report

Pages: 9

Uncertainty No Friend of the Stock, Expecting XMT-1522 to Clear Cohort 7 Over the Near Term

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 175

06/05/2018

Industry Report

Pages: 10

Biotechnology -ASCO Presentations Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 176

05/17/2018

Company Report

Pages: 8

ASCO Abstract: Signs of Activity at Lower Doses; No DLT; and Clean Safety Profile

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 177

05/15/2018

Company Report

Pages: 9

No DLT Is Good DLT; Both High DAR Constructs Humming Along

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 178

05/15/2018

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 179

05/15/2018

Company Report

Pages: 7

Continuing Dose Escalation Evidence of 1522’s Favorable Tolerability Profile

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Mersana Therapeutics, Inc.

Industry: Unclassified

Record: 180

05/11/2018

Industry Report

Pages: 8

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party